Nyxoah price target lowered to $19 from $27 at Stifel

Stifel lowered the firm’s price target on Nyxoah (NYXH) to $19 from $27 and keeps a Buy rating on the shares. Additional data from Eli Lilly’s (LLY) SURMOUNT-OSA trial that was released late Friday afternoon raises more questions for Inspire Medical (INSP) and the HGNS market than it offers answers, the analyst tells investors. The incremental information, notably the percent of obstructive sleep apnea, or OSA, patients no longer considered moderate or severe at week 52, makes the firm “more concerned on out-year numbers,” and it lowered estimates and targets for both Inspire and Nyxoah, the analyst added.